journal
MENU ▼
Read by QxMD icon Read
search

Oncology (Williston Park, NY)

journal
https://www.readbyqxmd.com/read/29299885/developments-in-breast-cancer-2017-2018-new-drugs-new-drug-classes-and-the-prospect-of-more-to-come
#1
Virginia G Kaklamani
No abstract text is available yet for this article.
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297175/sipuleucel-t-when-and-for-whom-to-recommend-it
#2
Susan F Slovin
Multiple immunotherapy platforms have been investigated for prostate cancer, but sipuleucel-T still remains the sole approved autologous cellular immune product that can be used in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. While preliminary data for specific checkpoint inhibitors suggest benefit for some patients, leading to durable responses, it has been clear that sipuleucel-T can affect not only the intratumoral milieu but also systemic immune populations...
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297174/emergence-of-a-novel-staging-system-for-oropharyngeal-squamous-cell-carcinoma-based-on-hpv-status
#3
Aru Panwar, Erik Interval, William M Lydiatt Emba
The staging of oropharyngeal squamous cell carcinoma has undergone key changes in the eighth edition of the American Joint Committee on Cancer Staging Manual, set to take effect January 1, 2018. The most significant change relates to the development of a novel staging system for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinomas, distinct from that for non-HPV-associated squamous cell carcinomas of the oropharynx. We describe the revised staging parameters and the rationale in support of the changes...
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297173/optimizing-treatment-approaches-in-advanced-renal-cancer
#4
Juan C Osorio, Robert J Motzer, Martin H Voss
Over the last decade, improved understanding of canonical pathways implicated in the unique biology of renal cell carcinoma (RCC) has fueled the development of several new approaches to treatment for this malignancy. Development of tyrosine kinase inhibitors; mammalian target of rapamycin inhibitors; and, more recently, targeted immunotherapies such as checkpoint inhibitors has had a major impact on the natural history of this disease. Clinical prognostic models also have played a central role in the management of metastatic disease, as well as in the design and interpretation of clinical trials...
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297172/radiation-dermatitis-recognition-prevention-and-management
#5
Jonathan Leventhal, Melissa Rasar Young
Radiation therapy (RT) is a frequently used modality for cancer treatment. Acute and/or chronic skin changes may occur and carry risk of influencing quality of life during and after completion of RT. Radiation reactions may lead to delays in treatment, diminished cosmesis, and functional deficits. Lifestyle factors, treatment modalities, topical agents, and, in some cases, wound dressings may be utilized to help prevent or ameliorate radiation-induced skin reactions. While rigorous evidence supporting specific interventions may be lacking or contradictory, this article summarizes the current knowledge of the etiology, manifestations, and interventions available for prevention and management of radiation dermatitis...
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297171/treatment-of-hiv-associated-lymphomas-the-latest-approaches-for-optimizing-outcomes
#6
Natasha B Hunter, Samantha Vogt, Richard F Ambinder
Treatment outcomes for patients with HIV-related lymphoma have improved since the advent of combination antiretroviral therapy. Standard regimens, including intensive regimens, are being used with encouraging results in patients with diffuse large B-cell lymphoma, Burkitt lymphoma, Hodgkin lymphoma, and primary central nervous system lymphoma. Approaches to salvage therapy also parallel those used in patients without HIV infection, including autologous and allogeneic hematopoietic stem cell transplant. Drug interactions with particular antiretrovirals warrant close attention...
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297170/deciding-the-duration-of-adjuvant-chemotherapy-in-a-patient-with-stage-iii-colon-cancer-when-can-less-be-more
#7
Neel D Trivedi, John L Marshall
No abstract text is available yet for this article.
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297169/clinical-decision-making-in-surveillance-of-non-muscle-invasive-bladder-cancer-the-evolving-roles-of-urinary-cytology-and-molecular-markers
#8
Tahlita C M Zuiverloon, Florus C de Jong, Dan Theodorescu
Cystoscopy and urine cytology are the gold-standard tests for detection of recurrent disease during follow-up in patients with a history of non-muscle-invasive bladder cancer (NMIBC). High associated costs, as well as side effects, have driven the desire for inexpensive, noninvasive, accurate, and easy-to-use urine markers to detect bladder cancer recurrence. While many urine markers have been developed, very few have been clinically implemented. In this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation...
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29297168/sio-president-lynda-balneaves-hopes-to-continue-work-on-expanding-the-society-s-reach
#9
Lynda Balneaves
No abstract text is available yet for this article.
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29181836/strategies-for-addressing-cancer-patients-complaints-of-fatigue
#10
Catherine B Saiki, Julie M Waldfogel, Elizabeth K Lee, Thomas J Smith
Cancer-related fatigue is a complex and common symptom for cancer patients. This article reviews important topics that oncology practitioners should know to better manage fatigue in this patient population. Our discussion includes identification and assessment of fatigue severity, as well as screening for comorbid conditions that may be contributing to an individual patient's fatigue. Finally, we review nonpharmacologic and pharmacologic interventions for the treatment of cancer-related fatigue and the associated literature supporting their effectiveness...
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29179253/mucosal-melanoma-new-insights-and-therapeutic-options-for-a-unique-and-aggressive-disease
#11
REVIEW
Benjamin A Lerner, Latoya A Stewart, David P Horowitz, Richard D Carvajal
Mucosal melanoma is a rare disease that is distinct from melanomas arising at other sites in the body. While melanocytes are most abundant in the skin, they can be found in smaller numbers in the mucous membranes, as well as in the eye. There are epidemiologic, genetic, and other physiologic differences between melanomas arising from melanocytes at these various sites, and these differences have important implications for both disease prognosis and treatment. Here, we review the features of mucosal melanoma that distinguish it from melanomas arising at other sites, and we highlight recent biological discoveries and emerging treatment options for this aggressive disease...
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29179252/counterpoint-which-treatment-modality-for-localized-prostate-cancer-yields-superior-quality-of-life-radiotherapy-or-prostatectomy
#12
Judd W Moul
No abstract text is available yet for this article.
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29179251/point-which-treatment-modality-for-localized-prostate-cancer-yields-superior-quality-of-life-radiotherapy-or-prostatectomy
#13
James B Yu, Daniel Hamstra
No abstract text is available yet for this article.
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29179250/pi3k-inhibitors-understanding-toxicity-mechanisms-and-management
#14
REVIEW
I Brian Greenwell, Andrew Ip, Jonathon B Cohen
The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment. Idelalisib was the first PI3K inhibitor approved by the US Food and Drug Administration and is utilized in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. Copanlisib has subsequently been approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies. There are multiple other PI3K agents currently in development; these target various combinations of PI3K isoforms...
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29179249/judy-garber-on-parp-inhibitors-for-triple-negative-breast-cancer
#15
Judy Garber
No abstract text is available yet for this article.
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29179248/radical-prostatectomy-for-patients-with-oligometastatic-prostate-cancer
#16
REVIEW
Ardalan E Ahmad, Ricardo Leão, Robert J Hamilton
Cancer progresses in a stepwise fashion. Oligometastatic cancer is an intermediate stage of tumor spread between localized disease and disseminated metastases. Oligometastatic prostate cancer is defined as up to five extrapelvic lesions on conventional imaging. There are controversies surrounding the management of this malignancy, but retrospective and population-based studies suggest a role for radical prostatectomy. Despite insufficient data to draw conclusions regarding the effectiveness of aggressive therapies on overall or cancer-specific survival of patients with oligometastatic prostate cancer, current studies suggest that surgery decreases tumor burden, disease-related morbidity, and the need for palliative surgical intervention, while increasing the period of time to development of castration-resistant disease...
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29179247/the-developing-role-of-anti-epidermal-growth-factor-receptor-agents-in-the-treatment-of-advanced-or-metastatic-colorectal-cancer
#17
Carling Ursem, Alan P Venook
The first studies of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer were begun before the predictive role of RAS mutations had been elucidated. Secondary analyses of many large randomized trials have shown that mutations in exons 2-4 of KRAS and NRAS, BRAF V600E mutation, and right-sided primary tumor all predict lack of response to EGFR inhibition in the first-line setting. However, even in patient populations defined by a lack of these negative predictors, there is still not uniform response to anti-EGFR therapy...
November 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29083471/counterpoint-early-salvage-vs-adjuvant-radiotherapy-for-high-risk-prostate-cancer
#18
Wayland J Wu, Louis Potters
No abstract text is available yet for this article.
October 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29083470/point-early-salvage-vs-adjuvant-radiotherapy-for-high-risk-prostate-cancer
#19
Rahul Tendulkar
No abstract text is available yet for this article.
October 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29083469/nonoperative-management-of-rectal-cancer-a-modern-perspective
#20
REVIEW
Yushen Qian, Alexander L Chin, Diego A S Toesca, Albert C Koong, Daniel T Chang
Nonoperative management of rectal cancer is an emerging treatment approach that aims to enable carefully selected patients to avoid the morbidity of radical surgical resection, while benefiting from the same excellent rates of tumor control achieved with radical surgery-based combined-modality therapy. The success of nonoperative management in this setting is based on the accurate assessment of tumor eradication after chemoradiotherapy, without pathologic verification. Therefore, clinical evidence of complete response-based on physical examination, endoscopic procedures, and imaging-must be utilized as a marker to predict for pathologic complete response and thus help select the patients who are most appropriate for nonoperative management...
October 15, 2017: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"